{
    "clinical_study": {
        "@rank": "58784", 
        "acronym": "WUJING", 
        "brief_summary": {
            "textblock": "A Multi-center, III Phase\uff0cRandomized Controlled Clinical Study of Capecitabine Beats\n      Chemotherapy After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer"
        }, 
        "brief_title": "A Multi-center, III Phase\uff0cRandomized Controlled Clinical Study of Capecitabine Beats Chemotherapy After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Breast Cancer", 
            "Capecitabine", 
            "TNBC"
        ], 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female;\n\n          -  aged 18 - 70 years old;\n\n          -  Histological confirmed with unilateral invasive carcinoma (all pathological types are\n             applicable);\n\n          -  Newly diagnosed conditions allowing direct surgery without any absolute\n             contraindication for surgery;\n\n          -  No mass or microscopic tumor residue after surgery resection;\n\n          -  Initiate adjuvant chemotherapy within 30 days after surgery;\n\n          -  Axillary lymph node positive (including the sentinel lymph node positive and lymph\n             node positive after axillary dissection), for example, axillary lymph node negative\n             requires that primary tumor size must be greater than 1cm;\n\n          -  Definite reports on ER/PR(progesterone receptor)/Her2 receptor showing all ER/PR/Her2\n             negative (specific definitions: immunohistochemical detection of ER <10% tumor cells\n             is defined as ER negative, PR <10% positive tumor cells is defined as PR-negative,\n             Her2 is 0~1+ or 2+ but determined negative via FISH or CISH detected (no\n             amplification) is defined as Her2 negative);\n\n          -  No relevant clinical or imaging evidence of metastasis showing in the preoperative\n             examination (M0);\n\n          -  Without peripheral neuropathy;\n\n          -  ECOG performance score is 0 or 1;\n\n          -  Postoperative recovery was good and an interval of at least one week since the\n             surgery is necessary;\n\n          -  White blood cell count> 4 \u00d7 10^9/l, neutrophil count> 2 \u00d7 10^9/l, platelet count> 100\n             \u00d7 10^9/l and hemoglobin 9g/dl);\n\n          -  ASAT and ALAT <1.5 folds of the upper limit of normal values, alkaline phosphatase\n             <2.5 folds of the upper limit of normal values, total bilirubin <1.5 folds of the\n             upper limit of normal values;\n\n          -  Serum creatinine <1.5 folds of the upper limit of normal value;\n\n          -  Women at childbearing age should take contraception measures during treatment;\n\n          -  Cardiac function: echocardiographic examination showed LEVF> 50%;\n\n          -  Informed consent form signed.\n\n        Exclusion Criteria:\n\n          -  Bilateral breast cancer or carcinoma in situ (DCIS / LCIS);\n\n          -  Metastasis at any location;\n\n          -  Any tumor > T4a (UICC1987) (accompanied by skin involvement, lump adhesion and\n             fixation, inflammatory breast cancer);\n\n          -  Any of ER, PR or Her-2 is positive;\n\n          -  Contralateral breast clinically or radiologically suspected to be malignant but not\n             confirmed which needs a biopsy;\n\n          -  Previous neoadjuvant therapy, including chemotherapy, radiotherapy and hormone\n             therapy;\n\n          -  Previously suffering from malignant tumors (except for basal cell carcinoma and\n             cervical carcinoma in situ), including contralateral breast cancer;\n\n          -  Already enrolled into other clinical trials;\n\n          -  Severe systemic disease and/or uncontrollable infection, unable to be enrolled in\n             this study LEVF <50% (echocardiography);\n\n          -  Suffering from severe cardiovascular and cerebrovascular diseases within six months\n             before the randomization (such as: unstable angina, chronic heart failure,\n             uncontrollable high blood  pressure > 150/90mmHg, myocardial infarction or brain\n             vascular accident);\n\n          -  Known allergic to taxane and anthracycline agents;\n\n          -  Women at childbearing age refuse to take contraception measures during the treatment\n             and 8 weeks after completion of treatment;\n\n          -  Pregnant and breast-feeding women;\n\n          -  Pregnancy test showed positive results before drug administration after enrolling in\n             to the study; With mental illness and cognitive impairment, unable to understand\n             trial protocol and side effects and complete trial protocol and follow-ups\n             (systematic evaluation is required before recruiting into this study);\n\n          -  Without personal freedom and independent civil capacity."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Breast cancer patients of vascular endocrine surgery department in Xijing Hospital"
            }
        }, 
        "enrollment": {
            "#text": "340", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02012634", 
            "org_study_id": "TPYS-01"
        }, 
        "intervention_browse": {
            "mesh_term": "Capecitabine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Breast Cancer", 
            "Capecitabine", 
            "TNBC\uff08Triple Negative Breast Cancer\uff09"
        ], 
        "lastchanged_date": "December 9, 2013", 
        "location": {
            "contact": {
                "email": "nanlin-74@163.com", 
                "last_name": "Nanlin Li, Ph.D", 
                "phone": "+86-137-0911-3279"
            }, 
            "contact_backup": {
                "email": "weihonglianghaoren@163.com", 
                "last_name": "Hongliang Wei, Master", 
                "phone": "+86-186-2963-7040"
            }, 
            "facility": {
                "address": {
                    "city": "Xi`an", 
                    "country": "China", 
                    "state": "Shaanxi", 
                    "zip": "710032"
                }, 
                "name": "Xijing Hospital \uff0c Fourth Military Medical University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Multi-center, III Phase\uff0cRandomized Controlled Clinical Study of Capecitabine Beats Chemotherapy After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer", 
        "overall_contact": {
            "email": "weihonglianghaoren@163.com", 
            "last_name": "Hongliang Wei, Mster", 
            "phone": "+86-18829584958"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "PFS was defined as the time from the date of randomization until the date of disease progression at any site including distant metastasis or second primary tumors or death\uff0c assessed up to 3 years", 
            "measure": "PFS\uff08Progression-free survival\uff09", 
            "safety_issue": "Yes", 
            "time_frame": "Progression-free survival\uff1atime from the date of randomization until the date of disease progression\uff0cassessed up to 3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02012634"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Xijing Hospital", 
            "investigator_full_name": "LiNanlin,Ph.D, Chief Physician,Clinical Professor", 
            "investigator_title": "The department of Vascular endocrine surgery", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Xijing Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Roche Pharma AG", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Xijing Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2013"
    }
}